G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT

PHASE2/PHASE3CompletedINTERVENTIONAL
Enrollment

202

Participants

Timeline

Start Date

April 18, 2016

Primary Completion Date

September 30, 2019

Study Completion Date

September 30, 2021

Conditions
Myelodysplastic SyndromeAllogeneic Hematopoietic Stem Cell TransplantationConditioning
Interventions
DRUG

Decitabine

Decitabine was administered at 20mg/m2/day on days -14 and -10.

DRUG

Busulfan (BU)

Busulfan was administered at 3.2 mg/kg/day on days -7 to -4.

DRUG

Cyclophosphamide (CY)

Cyclophosphamide was administered at 60 mg/kg/day on days -3 to -2.

DRUG

Granulocyte Colony-Stimulating Factor(G-CSF)

G-CSF was administered at 5-10 ug/kg/day on days -17 and -10. When white blood cell is more than 20G/L, stop using G-CSF.

Trial Locations (1)

510515

Department of Hematology,Nanfang Hospital, Southern Medical University, Guangzhou

All Listed Sponsors
collaborator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

OTHER

collaborator

Institute of Hematology & Blood Diseases Hospital, China

OTHER

collaborator

Peking University People's Hospital

OTHER

collaborator

First People's Hospital of Chenzhou

OTHER

collaborator

Liuzhou Workers' Hospital

OTHER_GOV

lead

Nanfang Hospital, Southern Medical University

OTHER

NCT02744742 - G-CSF+Decitabine+BUCY vs BUCY Conditioning Regimen for RAEB-1, REAB-2 and AML Secondary to MDS Undergoing Allo-HSCT | Biotech Hunter | Biotech Hunter